Xilio Therapeutics, Inc. XLO
8.68 USD +0.69 (+8.64%)
At closeNov 3, 2026, 4:02 PM EST
8.68 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
7.94 Day range 8.85
6.47 52-week range 12.01
- YTD
- -3.13%
- 1 year
- -27.06%
Analyst view
Consensus: buy
Buy
Price target (mean) 4.50 -48.2% downside
Now 8.68
- Target (low)
- 4.00
- Target (mean)
- 4.50
- Target (high)
- 5.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.24 | -0.24 – -0.24 | -0.64 | +62.5% | 0 | 0.0% | 1 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | -1.21 | -1.21 – -1.21 | -2.78 | +56.5% | 7.69M | 0.0% | 1 |
| Next year | -0.67 | -0.67 – -0.67 | -1.21 | +44.6% | 36.07M | +368.7% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Raymond James | Maintained | Outperform | Outperform |
| May 30, 2023 | Chardan Capital | Reiterated | Buy | Buy |
| May 11, 2023 | Chardan Capital | Reiterated | — | Buy |
| Jan 27, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Dec 21, 2022 | Chardan Capital | Initiated | — | Buy |
| Nov 10, 2022 | Raymond James | Maintained | — | Outperform |
| Aug 10, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Jan 10, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Nov 16, 2021 | Raymond James | Initiated | — | Outperform |
| Nov 16, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Nov 16, 2021 | Morgan Stanley | Initiated | — | Overweight |